Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease

    NEXT STORY
    Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7 Superfamily
    PREV STORY
    AB Science announces that new results published in the peer-reviewed Journal of Alzheimer’s Disease support masitinib’s potential mode of action in Alzheimer’s Disease
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Orion Group Half-Year Financial Report 1-6/2020

    author_avatar
    NASDAQ Market News

    Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis (PVNS)

    SOUTH SAN FRANCISCO, Calif., April 10, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. ...

    author_avatar
    NASDAQ Market News

    Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T™ Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

    author_avatar
    NASDAQ Market News